Literature DB >> 12565990

No evidence of involvement of germline BACH1 mutations in Finnish breast and ovarian cancer families.

S-M Karppinen1, J Vuosku, K Heikkinen, M Allinen, R Winqvist.   

Abstract

Recently BACH1, a novel putative DNA helicase mapping to chromosome 17q22, was reported to interact specifically with BRCA1, and was suggested to be a candidate gene for predisposition to breast and ovarian cancers. Here, we screened 214 breast and ovarian cancer patients from 151 Finnish families for germline BACH1 mutations by utilising conformation-sensitive gel electrophoresis (CSGE) and genomic sequencing analysis. Four sequence alterations were observed in the exon regions of BACH1, three of which have been previously reported and were classified as polymorphisms. In 1 patient, a novel heterozygous 3101C>T variant was observed resulting in a proline to leucine substitution at codon 1034 (Pro1034Leu). This amino acid change occurs in the BRCA1 binding domain of the BACH1 protein. Although the 3101C>T transition was also found in one of the 304 control individuals with an unknown cancer status, it still remains possible that this alteration could represent a rare disease-related allele in the population. Functional assays are needed to resolve the biological significance of this novel BACH1 missense variant. Altogether, the available data suggest that germline mutations in BACH1 are extremely rare.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12565990     DOI: 10.1016/s0959-8049(02)00498-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

Review 1.  G-quadruplex nucleic acids and human disease.

Authors:  Yuliang Wu; Robert M Brosh
Journal:  FEBS J       Date:  2010-07-29       Impact factor: 5.542

2.  Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families.

Authors:  Szilvia Solyom; Katri Pylkäs; Robert Winqvist
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

3.  A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function.

Authors:  Arcangela De Nicolo; Mariella Tancredi; Grazia Lombardi; Cristina Chantal Flemma; Serena Barbuti; Claudio Di Cristofano; Bijan Sobhian; Generoso Bevilacqua; Ronny Drapkin; Maria Adelaide Caligo
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

4.  The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations.

Authors:  Sharon Cantor; Ronny Drapkin; Fan Zhang; Yafang Lin; Juliana Han; Sushmita Pamidi; David M Livingston
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

5.  BACH1 Ser919Pro variant and breast cancer risk.

Authors:  Pia Vahteristo; Kristiina Yliannala; Anitta Tamminen; Hannaleena Eerola; Carl Blomqvist; Heli Nevanlinna
Journal:  BMC Cancer       Date:  2006-01-24       Impact factor: 4.430

6.  Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer.

Authors:  Aaron G Lewis; James Flanagan; Anna Marsh; Gulietta M Pupo; Graham Mann; Amanda B Spurdle; Geoffrey J Lindeman; Jane E Visvader; Melissa A Brown; Georgia Chenevix-Trench
Journal:  Breast Cancer Res       Date:  2005-10-21       Impact factor: 6.466

7.  BRIP1 overexpression is correlated with clinical features and survival outcome of luminal breast cancer subtypes.

Authors:  Ishita Gupta; Allal Ouhtit; Adil Al-Ajmi; Syed Gauhar A Rizvi; Hamad Al-Riyami; Marwa Al-Riyami; Yahya Tamimi
Journal:  Endocr Connect       Date:  2017-11-14       Impact factor: 3.335

8.  Inherited and acquired alterations in development of breast cancer.

Authors:  Piera Rizzolo; Valentina Silvestri; Mario Falchetti; Laura Ottini
Journal:  Appl Clin Genet       Date:  2011-11-14

9.  BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study.

Authors:  Bernd Frank; Kari Hemminki; Alfons Meindl; Barbara Wappenschmidt; Christian Sutter; Marion Kiechle; Peter Bugert; Rita K Schmutzler; Claus R Bartram; Barbara Burwinkel
Journal:  BMC Cancer       Date:  2007-05-15       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.